Cryopreserved Platelet Clinical Trial Ends Early After Meeting Primary Endpoint
April 22, 2025
Cellphire Therapeutics, a clinical stage biotechnology company developing next-generation platelet-derived therapies,
announced the early termination of the company’s phase 2/3 CRYPTICS clinical trial on Tuesday after a pre-planned interim analysis showed the study met its primary efficacy endpoint. An independent data monitoring committee recommended stopping the trial early based on safety and efficacy data from more than 150 participants.
The CRYPTICS (Cryopreserved Platelet Trial for Control of Bleeding in Surgery) study evaluated the safety and efficacy of
CLPH-511, Cellphire’s investigational cryopreserved platelet product, for the treatment of uncontrolled hemorrhage in patients undergoing cardiopulmonary bypass surgery. The study demonstrated statistical non-inferiority of CLPH-511 compared to standard room-temperature platelet products for controlling 24-hour chest tube drainage.
Cellphire expects to complete final study visits and data collection during the second quarter of 2025. Additional information about the trial is available online.
